Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: Discordant enantioselectivity versus reduction of plasma aldosterone

Endocrinology

Volumn 149, Issue 1, 2008, Pages 28-31

  Minnaard Huiban, Monica ^a   Emmen, Judith M A ^a   Roumen, Luc ^a,b,c   Beugels, Ilona P E ^a   Cohuet, Géraldine M S ^a   Van Essen, Helma ^a   Ruijters, Eveline ^a   Pieterse, Koen ^b   Hilbers, Peter A J ^b   Ottenheijm, Harry C J ^a   Plate, Ralf ^c   De Gooyer, Marcel E ^c   Smits, Jos F M ^a   Hermans, J J Rob ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CANRENOATE POTASSIUM; COLLAGEN; FADROZOLE; MINERALOCORTICOID ANTAGONIST;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENANTIOMER; ENANTIOSELECTIVITY; FIBROSING ALVEOLITIS; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; KIDNEY TUBULE EXCRETION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; TREATMENT DURATION;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CANRENOATE POTASSIUM; COLLAGEN TYPE I; COLLAGEN TYPE III; DRUG EVALUATION, PRECLINICAL; FADROZOLE; FIBROSIS; GENE EXPRESSION REGULATION; HEART; HEART FAILURE; MALE; MYOCARDIUM; RATS; RATS, INBRED SHR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 37549047239     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0584     Document Type: Article

References (16)

1. Williams JS, Williams GH 2003 50th Anniversary of aldosterone. J Clin Endocrinol Metab 88:2364-2372
2. Swedberg K EP, Kjekshus J, Wilhelmsen L 1990 Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82:1730-1736
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321
5. Struthers AD 1999 Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Br J Clin Pharmacol 47:479-482
6. Zannad F, Alla F, Dousset B, Perez A, Pitt B 2000 Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102:2700-2706
7. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M 2005 Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112:2940-2945
8. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Muller DN 2005 Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111:3087-3094
9. Menard J, Gonzalez MF, Guyene TT, Bissery A 2006 Investigation of aldosterone-synthase inhibition in rats. J Hypertens 24:1157-1163
10. Menard J, Pascoe L 2006 Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition? J Hypertens 24:993-997
11. Heyen JR, Blasi ER, Nikula K, Rocha R, Daust HA, Frierdich G, Van Vleet JF, De Ciechi P, McMahon EG, Rudolph AE 2002 Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol 283:H1775-H1784
12. Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A 1991 Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem 34:725-736
13. Hermans JJ, van Essen H, Struijker-Boudier HA, Johnson RM, Theeuwes F, Smits JF 2002 Pharmacokinetic advantage of intrapericardially applied substances in the rat. J Pharmacol Exp Ther 301:672-678
14. Baumann M, Janssen BJ, Hermans JR, Peutz-Kootstra C, Witzke O, Smits JF, Struijker Boudier HA 2007 Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 25:207-215
15. Connell JM, Fraser R, MacKenzie S, Davies E 2003 Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension? Hypertension 41:993-999
16. Swynghedauw B 1999 Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215-262